References
1. Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, et al.
Comparison of diagnostic accuracy of early screening for pre-eclampsia
by NICE guidelines and a method combining maternal factors and
biomarkers: results of SPREE. Ultrasound in obstetrics & gynecology :
the official journal of the International Society of Ultrasound in
Obstetrics and Gynecology. 2018;51(6):743-50.
2. Chappell LC, Brocklehurst P, Green ME, Hunter R, Hardy P, Juszczak E,
et al. Planned early delivery or expectant management for late preterm
pre-eclampsia (PHOENIX): a randomised controlled trial. Lancet (London,
England). 2019;394(10204):1181-90.
3. National Institute for Health and Care Excellence. Hypertension in
Pregnancy: Diagnosis and Management. 2019.
4. Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von
Dadelszen P, et al. Prediction of complications in early-onset
pre-eclampsia (PREP): development and external multinational validation
of prognostic models. BMC medicine. 2017;15(1):68.
5. von Dadelszen P, Payne B, Li J, Ansermino JM, Broughton Pipkin F,
Cote AM, et al. Prediction of adverse maternal outcomes in
pre-eclampsia: development and validation of the fullPIERS model. Lancet
(London, England). 2011;377(9761):219-27.
6. Tranquilli AL, Dekker G, Magee L, Roberts J, Sibai BM, Steyn W, et
al. The classification, diagnosis and management of the hypertensive
disorders of pregnancy: A revised statement from the ISSHP. Pregnancy
hypertension. 2014;4(2):97-104.
7. Thangaratinam S, Allotey J, Marlin N, Mol BW, Von Dadelszen P,
Ganzevoort W, et al. Development and validation of Prediction models for
Risks of complications in Early-onset Pre-eclampsia (PREP): a
prospective cohort study. Health technology assessment (Winchester,
England). 2017;21(18):1-100.
8. Collins GS, Ogundimu EO, Altman DG. Sample size considerations for
the external validation of a multivariable prognostic model: a
resampling study. Statistics in medicine. 2016;35(2):214-26.
9. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L,
et al. Diagnostic accuracy of placental growth factor in women with
suspected preeclampsia: a prospective multicenter study. Circulation.
2013;128(19):2121-31.
10. DW Hosmer SL. Applied Logistic Regression. 2nd Edition ed. New York,
NY: John Wiley and Sons; 2000.
11. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al.
Placental growth factor testing to assess women with suspected
pre-eclampsia: a multicentre, pragmatic, stepped-wedge
cluster-randomised controlled trial. Lancet (London, England).
2019;393(10183):1807-18.
12. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler
H, et al. The sFlt-1/PlGF ratio in different types of hypertensive
pregnancy disorders and its prognostic potential in preeclamptic
patients. American journal of obstetrics and gynecology.
2012;206(1):58.e1-8.
13. Lou WZ, Jiang F, Hu J, Chen XX, Song YN, Zhou XY, et al. Maternal
Serum Angiogenic Factor sFlt-1 to PlGF Ratio in Preeclampsia: A Useful
Marker for Differential Diagnosis and Prognosis Evaluation in Chinese
Women. Disease markers. 2019;2019:6270187.
14. Meler E, Scazzocchio E, Peguero A, Triunfo S, Gratacos E, Figueras
F. Role of maternal plasma levels of placental growth factor for the
prediction of maternal complications in preeclampsia according to the
gestational age at onset. Prenatal diagnosis. 2014;34(7):706-10.
Table 1: Maternal demographics and baseline characteristics at enrolment
(by expectant management groups)